Target for treating athersclerosis, obesity and type II diabetes
US6942967B1 · kind B1 · utility
2Cited by
1References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 29, 2000 |
| Grant date | Sep 13, 2005 |
| Priority date | — |
| Expiry date | Jun 29, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns the use of the apobec-1 protein or associated proteins for treating atherosclerosis and obesity, type II diabetes (non-insulin-dependent), or other diseases, characterised in particular by hyperlipidemia and/or hyperglycemia, caused for example by a level of chylomicrons and/or VLDL in the plasma above normal. The invention also concerns the cloning of the gene(s) of Anderson disease as target for treating atheroscelerosis, obesity and type II diabetes (non-insulin-dependent), or other diseases characterised in particular by hyperlipidemia and/or hyperglycermia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.